LiverLearning®: 2017 Hepatitis Debrief

This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.Michael W. Fried Insook Kim Insook Kim, PhD is a clinical pharmacology team leader for gastroenterology and hepatology products in the Office of Clinical Pharmacology at FDA. Since she joined FDA as a clinical pharmacology reviewer in 2007, she has been involved in numerous IND and NDA review and has provided regulatory and scientific guidance for product development in the areas of gastroenterology, hepatology, and inborn errors of metabolism.

LiverLearning®: AASLD/EASL Symposium: Non-invasive Assessment of Liver Disease

The Symposium will provide a broad overview on the diversity of noninvasive diagnostic approaches for assessing chronic liver disease in the U.S. and Europe. Experts will discuss the role and interpretation of noninvasive diagnostic test strategies in assessing the severity of disease associated with NAFLD, cirrhosis, and portal hypertension. These lectures — in conjunction with a panel discussion — will benefit all healthcare professionals using these novel tools in their clinical practice.Jayant A. Talwalker Sumeet K.

LiverLearning®: Hans Popper Basic Science SOA: Gut Microbiota and Liver

The intestinal microbiota and the human body have a symbiotic relationship, and a dysbalance of this delicate homeostasis can lead to disease. Liver diseases are associated with changes in the gut microbiota. Intestinal dysbiosis is characterized by bacterial overgrowth and changes in the microbiota composition. In addition, most chronic liver diseases are associated with intestinal barrier dysfunction. The contribution of intestinal dysbiosis to chronic liver disease goes beyond disruption of the intestinal barrier.

LiverLearning®: 2017 Global Forum: The Global Burden of Non-alcoholic Fatty Liver Disease

NAFLD affects 24% of the adult population worldwide. Additionally, about 10% of children and adolescents may have NAFLD. NAFLD is closely associated with type 2 diabetes and obesity. A proportion of subjects with NAFLD and non-alcoholic steatohepatitis (NASH) can develop progressive liver disease, cirrhosis and liver cancer. There are extensive efforts to develop non-invasive tests for NASH. Although no approved therapeutic options for NASH are yet available, a large number of clinical trials are underway.

LiverLearning®: HCV 2017 Treatment Symposium

This program will include discussions of recently approved regimens and challenging patient populations.  The emphasis in these lectures will be on clinical knowledge and application to individual patient management decisions, the AASLD-IDSA Guidance Panel treatment recommendations, and global perspectives on disease eradication strategies.Andrew J. Muir Andrew Muir, MD, FAASLD is a gastroenterologist whose research activitiesare focused on developing innovative treatments for a variety of liverdiseases. Through his work at the Durham Veterans Administration MedicalCenter, Dr.

Subscribe to